ClinicalTrials.gov
public full text
Public Domain
N-acetylcysteine Plus Deferoxamine for Patients With Hypotension
Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- N-acetylcysteine in endometriosis : : a systematic review of biological rationale and clinical evidence#1106666
- Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy#885177
- RAS Blockade at Bedtime Versus on Awakening for Aldosterone Breakthrough#832061
- Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)#835745
- Influence of n-Acetylcysteine Maintenance on Alcohol Effects#913815
Record · ID 893378
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive